5-gene signature (ANKRD29/CACNA2D2/DSP/HSD17B6/SPP1)

Overview

The 5-gene signature (ANKRD29/CACNA2D2/DSP/HSD17B6/SPP1) is a composite gene-expression signature used in recent biomedical research as a prognostic and tumor microenvironment–associated marker set, particularly in cancer studies. As a gene signature rather than a single gene product, it represents a coordinated expression pattern across five genes: ANKRD29, CACNA2D2, DSP, HSD17B6, and SPP1. In the studies provided, this signature was linked to tumor niche biology, immune infiltration, therapy response, and spatial compartmentalization of tumor tissues.

Among the five genes, SPP1 (Secreted phosphoprotein 1 (SPP1)) appears to be the most biologically prominent in the recent literature contexts. It has been associated with macrophage polarization, tumor progression, and immune-state remodeling, including signaling through the CD44/JAK2/STAT3 signaling pathway. The other genes in the signature were discussed mainly as part of a multigene predictive model, with CACNA2D2, DSP, HSD17B6, and ANKRD29 contributing to the signature’s ability to stratify disease states and infer tumor microenvironment dynamics.

Recent Publications Summary

Recent work involving this five-gene panel has been dominated by SPP1, which emerges across oncologic, metabolic, and neurodegenerative settings as a shared marker of inflammatory tissue remodeling. A review of secreted phosphoprotein-1 in malignancy frames dysregulated SPP1 expression as a contributor to pathogenic progression across diverse tumor types while noting that its adverse clinical effects remain incompletely characterized 42204033May. Mechanistic work in thyroid cancer supplied one such account: tumor-derived exosomal SPP1 drove macrophage M2 polarization through the CD44/JAK2/STAT3 signaling pathway, linking secreted SPP1 to immunosuppressive myeloid reprogramming and malignant progression 42153613May.

In lung adenocarcinoma, SPP1 signaling has been repeatedly tied to immunotherapy failure. Integration of bulk and single-cell transcriptomes across 31 datasets identified ZNF683+CD8+ T cell infiltration as a hallmark of immunotherapy responders and produced a ZNF683+CD8+ T cell-related risk score (ZNFRS) built with a StepCox[forward] + Ridge combination selected from 296 algorithm pairings; high-risk tumors showed a "cold" microenvironment with reduced immune infiltration, resistance to immune checkpoint blockade, and enhanced SPP1 signaling, and in vivo anti-SPP1 treatment suppressed tumor growth while restoring CD8+ T cell effector function 42115771May. A complementary multi-omics analysis centered on crosstalk between SPP1+ malignant cells and CXCR4+ tumor-associated macrophages as a predictor of immunotherapy response in this immunosuppressive microenvironment 42045760Apr. Together these studies position SPP1 not only as a prognostic readout but as a candidate therapeutic target for reversing resistance to cancer immunotherapy.

Two lung adenocarcinoma studies bear more directly on other members of the signature. A single-cell RNA sequencing and machine learning pipeline aimed at lymph node metastasis and cellular immunity nominated CACNA2D2 among eight prognostic genes (with RGS20, KYNU, RAET1E, FGF12, GJB2, FURIN, and GDF10); across four datasets, patients with high metastasis- and immune-related risk scores had higher mortality than low-risk patients, and functional follow-up focused on FURIN silencing and overexpression in invasion, metastasis, and lymphangiogenesis assays 41979566Apr. Separately, spatial and multi-omics transcriptomic dissection of platinum resistance used consensus clustering to define LUAD subtypes — with Cluster1 showing marked platinum resistance — and applied the Supervised Principal Component algorithm to build a five-gene predictive model validated by ROC analysis and by cisplatin IC50 shifts after gene manipulation in LUAD cell lines 41662930Feb.

Beyond oncology, SPP1 recurs as a progression biomarker in non-malignant disease. Multi-omics integration with machine learning in metabolic dysfunction-associated steatotic liver disease found SPP1 upregulated alongside AKR1B10 and COL1A2, with CYP2C19 downregulated, across the continuum from steatosis to steatohepatitis, fibrosis, and cirrhosis; these patterns were confirmed in vivo and in vitro, and AKR1B10 knockdown or CYP2C19 overexpression reduced hepatocellular lipid accumulation, oxidative stress, inflammatory responses, and lipogenic gene expression 42268665Jun. In the central nervous system, integrative analysis of human single-nuclei RNA sequencing across amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, aging, and Parkinson's disease resolved distinct microglial subpopulations and a shared cross-disease transcriptional program tied to inflammatory and neurodegenerative processes, with a machine learning framework discriminating neurodegenerative from control samples and SPP1 highlighted as a biomarker 42011986Apr.

Across these reports, the recurring methodological pattern is multi-omics integration — bulk, single-cell, single-nuclei, and spatial transcriptomics — coupled with machine learning-based feature selection and model construction, followed by targeted in vitro or in vivo validation. ANKRD29, DSP, and HSD17B6 were not individually characterized in this set of publications; the evidence base concentrates on SPP1, with CACNA2D2 appearing in a single prognostic gene panel.

What Changes, What Holds

1. SPP1 now looks like the dominant functional driver in this panel, not just one member of a prognostic set
NEW DIRECTION Recent work keeps the five-gene signature intact as a prognostic/tumor-microenvironment marker, but it shifts the practical center of gravity toward SPP1 as the biologically actionable component 42204033May42153613May. That does not overturn the baseline; it narrows where mechanistic attention should go and suggests the other four genes remain largely model features unless future studies assign them independent roles.

2. SPP1 is moving from readout to intervention target in immunotherapy resistance
NEW DIRECTION The new lung adenocarcinoma studies extend the baseline’s immune-infiltration theme by tying SPP1 to a cold, checkpoint-resistant state and showing that blocking it can restore CD8+ T-cell function 42115771May42045760Apr. That strengthens the idea that SPP1 marks tumor microenvironment remodeling, but it also adds a therapeutic angle the Overview did not yet claim: SPP1 may be used to reverse resistance, not only to predict it.

3. CACNA2D2 has only weakly emerged as a prognostic component, while the rest of the panel remains uncharacterized
REINFORCES The lung adenocarcinoma work does not displace the baseline, but it gives CACNA2D2 a narrower and more tentative role: one prognostic gene among several in a metastasis/immune-risk model 41979566Apr. At the same time, the absence of individual characterization for ANKRD29, DSP, and HSD17B6 leaves the original five-gene signature concept standing, with no new evidence that those genes have independent biology beyond model performance 41662930Feb.

4. SPP1 is now implicated as a shared marker of inflammatory remodeling across malignant and non-malignant disease
NEW DIRECTION The recent metabolic and neurodegenerative studies broaden the baseline beyond cancer, which had framed the signature mainly around tumor niche biology and immune infiltration 42268665Jun42011986Apr. That does not contradict the original account, but it adds a cross-disease interpretation: SPP1 may be a general marker of tissue remodeling and inflammatory state, not merely a cancer-associated prognostic signal.

5. Multi-omics machine learning is the main advance here, while the biological story remains centered on SPP1
METHOD These papers mainly change how the five-gene signature is being studied: bulk, single-cell, single-nuclei, and spatial data are being integrated with feature-selection pipelines and then validated experimentally 42115771May41662930Feb42011986Apr. That methodological shift sharpens confidence in the associations, but it does not yet resolve the baseline’s open question of whether ANKRD29, DSP, and HSD17B6 contribute independent biology or simply help the model classify states.

Overview update candidates: SPP1 as a candidate therapeutic target for reversing immunotherapy resistance; SPP1 as a cross-disease marker of inflammatory tissue remodeling; CACNA2D2 as a limited prognostic component in lung adenocarcinoma models.